Stock LYEL LYELL IMMUNOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq
Other stock markets
 16:15:00 2024-05-03 EDT 		5-day change 1st Jan Change
2.36 USD -1.67% Intraday chart for Lyell Immunopharma, Inc. +7.27% +21.65%
03-04 North American Morning Briefing : Stock Futures -2- DJ
02-28 Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
GL
North American Morning Briefing : Stock Futures -2-
DJ
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q4 Revenue $13,000
MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
GL
Lyell Immunopharma Announces Participation in March Investor Conferences
GL
Lyell Immunopharma Announces Participation in March Investor Conferences
AQ
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.
CI
MaxCyte's strategic platform licences redeem otherwise modest results
AN
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
GL
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from S&P Biotechnology Select Industry Index
CI
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
GL
HC Wainwright Trims Lyell Immunopharma's Price Target to $8 From $9, Maintains Buy Rating
MT
Lyell Immunopharma: Q3 Earnings Snapshot
AQ
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $25,000
MT
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
GL
SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors
PU
SITC 2023: Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYEL Stock
  4. News Lyell Immunopharma, Inc.